Opportunity Information: Apply for RFA CE 25 028
The CDC National Center for Injury Prevention and Control (NCIPC) is offering a cooperative agreement to support investigator-initiated effectiveness research focused on preventing polysubstance-impaired driving and its consequences, including crashes, nonfatal injuries, and deaths. In this opportunity, "polysubstance-impaired driving" specifically refers to driving while impaired by two or more substances at the same time, such as alcohol combined with opioids, or cannabis combined with alcohol. CDC is emphasizing that the current evidence base is thin when it comes to rigorous, real-world evaluations of strategies aimed at this growing and changing problem, especially as substance use patterns and legal environments continue to evolve.
The core purpose of the funding is to generate strong, practical evidence about what works to reduce polysubstance-impaired driving. CDC is looking for studies that carefully evaluate the effectiveness of strategies, programs, or policies (all grouped under the term "strategies") that could prevent polysubstance-impaired driving directly or reduce it indirectly by lowering excessive alcohol use, harmful substance use, or substance use disorders. The opportunity highlights that comprehensive evaluations are urgently needed, not only to determine whether strategies reduce impaired driving, but also to measure downstream safety outcomes like injury and mortality impacts.
Two broad categories of strategies are specifically called out as good candidates for evaluation. The first category is evidence-based alcohol-impaired driving strategies that may also reduce polysubstance-impaired driving. Examples provided include screening and brief intervention approaches (often used in healthcare or community settings to identify risky substance use and intervene early) and alternative transportation or transit programs that provide safer options when individuals might otherwise drive impaired. The second category includes strategies designed to prevent excessive alcohol use or harmful substance use more generally, with the expectation that these upstream approaches can also reduce polysubstance-impaired driving. Examples in this category include taxation or pricing policies for alcohol and cannabis, social norming campaigns that aim to shift perceptions and behaviors around substance use, and multi-component community coalition strategies such as Drug Free Communities-style efforts.
A major theme of the NOFO is equity and differential impact. CDC explicitly notes that polysubstance-impaired driving and related harms can fall disproportionately on certain populations, including American Indian and Alaska Native (AIAN) communities and rural populations, among others. Applicants are encouraged to examine whether strategies work similarly across different populations and contexts, and to assess impacts among groups that experience disproportionate harm. In practice, that means studies that do not just report overall average effects, but also investigate variation by geography, demographic group, or other factors tied to inequitable outcomes.
Administratively, this is a discretionary funding opportunity issued by the Centers for Disease Control and Prevention, using a cooperative agreement mechanism, which generally implies substantial federal involvement or collaboration during the project compared to a standard grant. The funding opportunity number is RFA CE 25 028, under CFDA 93.136, and the application deadline listed is 2024-12-02. The award ceiling is $350,000, and CDC expects to make one award, meaning the competition is likely to be highly selective and focused on a single, well-justified project with a rigorous evaluation plan.
Eligibility is broad and includes many types of applicants: state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); small businesses; and other entities, with eligibility described as unrestricted. This broad eligibility is consistent with CDC's interest in practical evaluations that may be conducted by universities, public agencies, tribal entities, nonprofits, or other organizations positioned to study real-world strategies in diverse settings.
Overall, the opportunity is aimed at closing a clear evidence gap: identifying and rigorously testing which interventions, policies, and community or system-level approaches actually reduce polysubstance-impaired driving and related injuries and deaths, and determining how well those strategies perform for the general population as well as for communities that are disproportionately affected.Apply for RFA CE 25 028
- The Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Effectiveness Research to Prevent Polysubstance-Impaired Driving" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.136.
- This funding opportunity was created on 2024-08-30.
- Applicants must submit their applications by 2024-12-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others, Unrestricted.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this CDC funding opportunity about?
This opportunity from the CDC National Center for Injury Prevention and Control (NCIPC) funds investigator-initiated effectiveness research to prevent polysubstance-impaired driving and its consequences, including crashes, nonfatal injuries, and deaths.
What does "polysubstance-impaired driving" mean in this opportunity?
In this NOFO, polysubstance-impaired driving specifically means driving while impaired by two or more substances at the same time, such as alcohol combined with opioids or cannabis combined with alcohol.
What is the main goal of the funded research?
The goal is to generate strong, practical, real-world evidence about what works to reduce polysubstance-impaired driving. CDC is looking for rigorous evaluations that can show whether a strategy is effective and what safety outcomes follow (for example, impacts on injuries and deaths).
What problem is CDC trying to address with this funding?
CDC emphasizes that the current evidence base is thin for rigorous, real-world evaluations of strategies targeting polysubstance-impaired driving, especially as substance use patterns and legal environments are changing. This funding is intended to close that evidence gap.
What kinds of approaches does CDC want evaluated?
CDC uses the term "strategies" to include programs, policies, and other approaches. The NOFO prioritizes careful evaluations of strategies that prevent polysubstance-impaired driving directly or reduce it indirectly by lowering excessive alcohol use, harmful substance use, or substance use disorders.
Are both direct and indirect prevention strategies allowed?
Yes. The opportunity supports evaluations of strategies that directly reduce impaired driving as well as upstream strategies that reduce excessive alcohol use or harmful substance use, with the expectation that those upstream changes can also reduce polysubstance-impaired driving.
What are the two broad categories of strategies specifically highlighted by CDC?
The NOFO calls out two major categories as good candidates for evaluation: (1) evidence-based alcohol-impaired driving strategies that may also reduce polysubstance-impaired driving, and (2) strategies designed to prevent excessive alcohol use or harmful substance use more generally.
What are examples of alcohol-impaired driving strategies that may also reduce polysubstance-impaired driving?
Examples provided include screening and brief intervention approaches (often in healthcare or community settings) and alternative transportation or transit programs that provide safer options when someone might otherwise drive impaired.
What are examples of upstream strategies that could reduce polysubstance-impaired driving indirectly?
Examples provided include taxation or pricing policies for alcohol and cannabis, social norming campaigns to shift perceptions and behaviors around substance use, and multi-component community coalition strategies such as Drug Free Communities-style efforts.
What outcomes does CDC want studies to measure?
CDC highlights the need to evaluate whether strategies reduce polysubstance-impaired driving and to measure downstream safety outcomes, including crashes, nonfatal injuries, and deaths.
Does CDC emphasize real-world effectiveness rather than controlled research settings?
Yes. The NOFO stresses the need for rigorous, real-world evaluations of strategies, reflecting CDC's interest in practical evidence that applies to changing substance use patterns and legal environments.
What does CDC mean by "equity" in this NOFO?
Equity is a major theme. CDC notes that polysubstance-impaired driving and related harms can fall disproportionately on certain populations (including American Indian and Alaska Native communities and rural populations, among others). Applicants are encouraged to examine whether strategies work similarly across populations and contexts and to assess impacts among groups experiencing disproportionate harm.
Is CDC interested in differential impacts across communities or populations?
Yes. CDC encourages studies that go beyond reporting overall average effects and that investigate variation by geography, demographic group, or other factors tied to inequitable outcomes.
What funding mechanism is being used?
This is a cooperative agreement. In general, a cooperative agreement implies substantial federal involvement or collaboration during the project compared to a standard grant.
What is the funding opportunity number and CFDA listing?
The funding opportunity number is RFA CE 25 028, and it is listed under CFDA 93.136.
What is the application deadline?
The listed application deadline is 2024-12-02.
How much funding is available per award?
The award ceiling listed is $350,000.
How many awards does CDC expect to make?
CDC expects to make one award, indicating the competition will likely be highly selective and focused on a single, well-justified project with a rigorous evaluation plan.
Who is eligible to apply?
Eligibility is broad and described as unrestricted. Eligible applicants include state, county, and local governments; special districts; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); small businesses; and other entities.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments and other tribal organizations are included in the eligibility list.
Are universities and colleges eligible?
Yes. Public and private institutions of higher education are included among eligible applicants.
Are nonprofits eligible even if they do not have 501(c)(3) status?
Yes. The eligibility list includes nonprofit organizations with or without 501(c)(3) status.
Can for-profit organizations and small businesses apply?
Yes. For-profit organizations (including those other than small businesses) and small businesses are included as eligible applicants.
Why does CDC emphasize the changing legal environment?
The NOFO notes that substance use patterns and legal environments continue to evolve, which contributes to the urgency of generating current, rigorous evidence on what strategies work in real-world contexts.
What makes an application especially aligned with CDC's priorities based on the NOFO summary?
Based on the information provided, strong alignment would include a rigorous evaluation of a clearly defined strategy, measurement of impaired driving and downstream safety outcomes, and an explicit plan to assess equity and differential impacts across populations or contexts.
Browse more opportunities from the same category: Health
Next opportunity: OVW Fiscal Year 2024 National Service Line for Incarcerated Survivors of Sexual Abuse Program
Previous opportunity: FY16 Capital and Debt Service and Americans with Disabilities Act Grant to Amtrak
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CE 25 028
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CE 25 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose Apply for RFA CE 25 149 Funding Number: RFA CE 25 149 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Environmental Health Specialists Network (EHS-Net) Practice-based Research to Improve Food Safety Apply for RFA EH 25 011 Funding Number: RFA EH 25 011 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $200,000 |
| Rigorously Evaluating Programs and Policies to Prevent Child Sexual Abuse and Problematic Sexual Behavior among Youth Apply for RFA CE 25 026 Funding Number: RFA CE 25 026 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $400,000 |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 25 021 Funding Number: RFA CE 25 021 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $400,000 |
| Evaluate STEADI-based Fall Prevention in Assisted Living Facilities Apply for RFA CE 25 027 Funding Number: RFA CE 25 027 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $700,000 |
| Formative Research of Community-led Primary Prevention Approaches to Address Elevated Risk of Intimate Partner Violence & Sexual Violence Apply for RFA CE 25 032 Funding Number: RFA CE 25 032 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $375,000 |
| Rigorously Evaluating Primary Prevention Strategies for Intimate Partner Violence and Sexual Violence Apply for RFA CE 25 031 Funding Number: RFA CE 25 031 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $500,000 |
| AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF) Apply for HRSA 25 046 Funding Number: HRSA 25 046 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Ending the HIV Epidemic in the U.S. – Ryan White HIV/AIDS Program Parts A and B Apply for HRSA 25 063 Funding Number: HRSA 25 063 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Ending the HIV Epidemic in the U.S. – Systems Coordination Provider Apply for HRSA 25 065 Funding Number: HRSA 25 065 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Ending the HIV Epidemic in the U.S. – Technical Assistance Provider Apply for HRSA 25 064 Funding Number: HRSA 25 064 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 25 017 Funding Number: HRSA 25 017 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 25 016 Funding Number: HRSA 25 016 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Cell and Gene Therapy (CGT) Access Model Apply for CMS 2P2 25 001 Funding Number: CMS 2P2 25 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $9,550,000 |
| USAID/Ethiopia Health Financing Activity Apply for 72066324RFA00012 Funding Number: 72066324RFA00012 Agency: Ethiopia USAID-Addis Ababa Category: Health Funding Amount: $40,000,000 |
| Tribal Institutional Review Board Establishment and Enhancement (TIRBEE) (R24 - Clinical Trial Not Allowed) Apply for PAR 24 260 Funding Number: PAR 24 260 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigating Mitochondrial-Nuclear Communication in AD/ADRD (R01 Clinical Trial Not Allowed) Apply for RFA AG 25 026 Funding Number: RFA AG 25 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| DFC Support Program – National Community Anti-Drug Coalition Institute (NCI) Apply for NCI NCI 24 001 Funding Number: NCI NCI 24 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $2,500,000 |
| PMI Case Management and Social Behavior Change Project Apply for 72061224RFA00003 Funding Number: 72061224RFA00003 Agency: Malawi USAID-Lilongwe Category: Health Funding Amount: $8,000,000 |
| Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) Apply for RFA NS 24 037 Funding Number: RFA NS 24 037 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CE 25 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.